VoICE Immunization Evidence

Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects

Authored by: Ray, G.T., Whitney, C., Fireman, B., et al

Appears in:

Key Idea

This study based on active surveillance in the US before and after introduction of PCV estimated 38,000 cases of invasive pneumococcal disease were averted in the first 5 years of vaccine use, and an additional 71,000 cases of disease were prevented through herd effects.

Key Idea

This study based on active surveillance in the US before and after introduction of PCV estimated 38,000 cases of invasive pneumococcal disease were averted in the first 5 years of vaccine use, at an estimated cost of US$112,000 per life year saved. However, after inclusion of 71,000 cases of disease that were prevented through herd effects, researchers estimate a cost of US$7,500 per life year saved.

Published In

Ray, G.T., Whitney, C., Fireman, B., et al 2006. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatric Infectious Disease Journal. 25:494-501.